Delivery Order SPE2DB24D2013-SPE2DB25FCKDM
- Not listed
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Lantus SoloStar insulin 100 unit/mL in 3 mL pens. This non-set-aside, competitively awarded contract carries a ceiling value of $2,171.76 with firm fixed pricing and an ultimate completion date of August 4, 2025. The pharmaceutical distributor will fulfill this order from its corporate office location in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency awarded a delivery order valued at $1,379.08 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL insulin pens (3mL format) on August 5, 2025, with completion scheduled for August 6, 2025. This non-competitive delivery order utilizes firm fixed pricing and represents a small-value pharmaceutical procurement supporting military and federal healthcare operations. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a $3,049.07 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Lantus SoloStar 100 Unit/mL 3mL insulin pens. This firm fixed price contract, with an ultimate completion date of July 24, 2025, represents a routine pharmaceutical procurement supporting federal medical supply needs. The award was competitively awarded with no set-aside designation, with performance to be executed at AmerisourceBergen's corporate office location...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Lantus SoloStar 100 Unit/mL insulin pens (3mL) with a contract ceiling value of $1,923.70. This firm fixed-price delivery order, which is set to be completed by September 9, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was made through competitive procurement without...
- The Defense Logistics Agency awarded a delivery order valued at $3,172.50 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL insulin pens on September 9, 2025, with completion targeted for September 10, 2025. This competitive, non-set-aside award utilizes firm fixed pricing and represents a direct fulfillment of pharmaceutical supply needs for the Department of Defense. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a $1,921.82 delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Lantus SoloStar 100 Unit/mL 3mL insulin pens. This is a firm fixed price, competitively awarded contract with a completion date of August 11, 2025, and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. No set-aside designation was applied to this award. This delivery order is issued under AmerisourceBergen Drug Corp's larger...
- The U.S. Defense Department's Medical Supply Chain awarded a $1,694.68 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/ML 3ML insulin pens on July 31, 2025, with an ultimate completion date of August 1, 2025. The contract was competitively awarded without set-aside provisions and will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $1,227.36 delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Lantus SoloStar 100 Unit/mL insulin pens (3mL formulation). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of August 26, 2025, with performance to be executed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $1,505.59 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Lantus SoloStar 100 Unit/mL 3mL insulin pens. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 through December 2026. The place of performance is listed as Conshohocken, Pennsylvania, with an ultimate completion...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/ML insulin pens, valued at $2,863.84, with an ultimate completion date of September 10, 2025. This firm fixed price, non-set-aside contract was awarded competitively on September 9, 2025, with performance to occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a continuation of the company's role as a critical...
- SPE2DB24D2013Indefinite Delivery Contract
- SPE2DB24D2013-SPE2DB25FCKDMDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Lantus SoloStar 100 Unit/ml insulin pens (3ml) with a ceiling value of $1,022.80. This is a firm fixed price delivery order with no set-aside designation, reflecting a competitive award to support federal medical procurement needs. The order is scheduled for completion by September 11, 2025, and will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a prime contractor for this comprehensive pharmaceutical support vehicle, AmerisourceBergen supplies a broad range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company's federal contract portfolio demonstrates extensive experience delivering specialized medications across multiple therapeutic domains, including diabetes treatments, to Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The firm fixed pricing structure and competitive award history underscore AmerisourceBergen's capability to meet federal medical supply requirements efficiently.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.0k | 9/10/25 |